NASDAQ:KALA - Kala Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$13.87 +1.14 (+8.96 %)
(As of 08/21/2018 04:00 PM ET)
Previous Close$12.73
Today's Range$12.68 - $14.14
52-Week Range$11.39 - $26.75
Volume668,800 shs
Average Volume239,766 shs
Market Capitalization$298.55 million
P/E Ratio-2.38
Dividend YieldN/A
BetaN/A
Kala Pharmaceuticals logoKala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. Its product candidates include KPI-121 1.0%, which has completed Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; INVELTYS that has completed Phase III clinical trials for the temporary relief of the signs and symptoms of dry eye disease; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Waltham, Massachusetts.

Receive KALA News and Ratings via Email

Sign-up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KALA
CUSIPN/A
Phone781-996-5252

Debt

Debt-to-Equity Ratio0.27
Current Ratio9.79
Quick Ratio9.79

Price-To-Earnings

Trailing P/E Ratio-2.38
Forward P/E Ratio-6.33
P/E GrowthN/A

Sales & Book Value

Annual Sales$40,000.00
Price / Sales8,526.58
Cash FlowN/A
Price / CashN/A
Book Value$3.66 per share
Price / Book3.79

Profitability

EPS (Most Recent Fiscal Year)($5.84)
Net Income$-42,210,000.00
Net MarginsN/A
Return on Equity-56.26%
Return on Assets-43.04%

Miscellaneous

Employees37
Outstanding Shares24,590,000
Market Cap$298.55 million

Kala Pharmaceuticals (NASDAQ:KALA) Frequently Asked Questions

What is Kala Pharmaceuticals' stock symbol?

Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA."

How were Kala Pharmaceuticals' earnings last quarter?

Kala Pharmaceuticals Inc (NASDAQ:KALA) announced its quarterly earnings data on Thursday, August, 9th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.50) by $0.11. View Kala Pharmaceuticals' Earnings History.

When is Kala Pharmaceuticals' next earnings date?

Kala Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November, 6th 2018. View Earnings Estimates for Kala Pharmaceuticals.

What price target have analysts set for KALA?

4 brokers have issued twelve-month price objectives for Kala Pharmaceuticals' shares. Their forecasts range from $19.00 to $47.00. On average, they expect Kala Pharmaceuticals' share price to reach $34.00 in the next year. This suggests a possible upside of 145.1% from the stock's current price. View Analyst Price Targets for Kala Pharmaceuticals.

What is the consensus analysts' recommendation for Kala Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kala Pharmaceuticals.

Who are some of Kala Pharmaceuticals' key competitors?

Who are Kala Pharmaceuticals' key executives?

Kala Pharmaceuticals' management team includes the folowing people:
  • Mr. Mark T. Iwicki, Chairman, Pres & CEO (Age 52)
  • Mr. Todd Bazemore, Chief Operating Officer (Age 48)
  • Dr. Kim Brazzell, Chief Medical Officer (Age 65)
  • Dr. Justin Hanes Ph.D., Founder & Chair of the Scientific Advisory Board
  • Ms. Mary Reumuth CPA, CFO & Treasurer (Age 43)

When did Kala Pharmaceuticals IPO?

(KALA) raised $90 million in an IPO on Thursday, July 20th 2017. The company issued 6,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.

Has Kala Pharmaceuticals been receiving favorable news coverage?

News articles about KALA stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Kala Pharmaceuticals earned a daily sentiment score of 0.20 on Accern's scale. They also gave news headlines about the company an impact score of 46.08 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future. View Recent Headlines for Kala Pharmaceuticals.

Who are Kala Pharmaceuticals' major shareholders?

Kala Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.85%), Millennium Management LLC (2.44%), Brown Advisory Inc. (0.86%), Wedbush Securities Inc. (0.23%), Bank of New York Mellon Corp (0.17%) and Alps Advisors Inc. (0.15%). Company insiders that own Kala Pharmaceuticals stock include Associates LLC Cdk, Longitude Capital Partners Ii,, Orbimed Advisors Llc and Rajeev M Shah. View Institutional Ownership Trends for Kala Pharmaceuticals.

Which institutional investors are selling Kala Pharmaceuticals stock?

KALA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, BlackRock Inc., Brown Advisory Inc. and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Kala Pharmaceuticals.

Which institutional investors are buying Kala Pharmaceuticals stock?

KALA stock was bought by a variety of institutional investors in the last quarter, including Alps Advisors Inc., Wedbush Securities Inc., Paloma Partners Management Co, Rhumbline Advisers and Bank of New York Mellon Corp. Company insiders that have bought Kala Pharmaceuticals stock in the last two years include Associates LLC Cdk, Longitude Capital Partners Ii,, Orbimed Advisors Llc and Rajeev M Shah. View Insider Buying and Selling for Kala Pharmaceuticals.

How do I buy shares of Kala Pharmaceuticals?

Shares of KALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kala Pharmaceuticals' stock price today?

One share of KALA stock can currently be purchased for approximately $13.87.

How big of a company is Kala Pharmaceuticals?

Kala Pharmaceuticals has a market capitalization of $298.55 million and generates $40,000.00 in revenue each year. The company earns $-42,210,000.00 in net income (profit) each year or ($5.84) on an earnings per share basis. Kala Pharmaceuticals employs 37 workers across the globe.

How can I contact Kala Pharmaceuticals?

Kala Pharmaceuticals' mailing address is 100 BEAVER STREET SUITE 201, WALTHAM MA, 02453. The company can be reached via phone at 781-996-5252 or via email at [email protected]


MarketBeat Community Rating for Kala Pharmaceuticals (NASDAQ KALA)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  118 (Vote Outperform)
Underperform Votes:  134 (Vote Underperform)
Total Votes:  252
MarketBeat's community ratings are surveys of what our community members think about Kala Pharmaceuticals and other stocks. Vote "Outperform" if you believe KALA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KALA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel